Pharmacokinetic-pharmacodynamic relationships for analgesics

被引:0
|
作者
Suri, A
Estes, KS
Geisslinger, G
Derendorf, H
机构
[1] NOVA SE UNIV, COLL PHARM, DEPT PHARMACEUT, FT LAUDERDALE, FL 33328 USA
[2] NOVA SE UNIV, COLL PHARM, DEPT PHARMACEUT SCI, FT LAUDERDALE, FL 33314 USA
[3] UNIV ERLANGEN NURNBERG, COLL MED, DEPT PHARMACOL, D-8520 ERLANGEN, GERMANY
关键词
analgesics; pharmacokinetics; pharmacodynamics;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major goal of current pain research is to develop scientifically-based guidelines to optimize selection of analgesic drug doses and control pain. Numerous clinical studies have shown that the drug dose required to effectively alleviate pain is often highly variable, both between patients and between pain episodes in individual patients. This high variability makes it difficult to predict appropriate dosing regimens that will adequately control pain in the individual patient, The result is a ''trial and error'' approach to analgesic therapy. Experimental tools that measure analgesic response and drug disposition after administration of analgesics can be used to better predict the therapeutic effects of analgesics in individual patients. The approach defines factors that contribute to variability in therapeutic response, Pharmacokinetic-pharmacodynamic (PK/PD) modeling involves analysis of drug disposition data and drug efficacy data, Modeling depends on sensitive and reliable methods to quantify both pain and plasma (or other body fluid) levels of analgesic agents. Two major approaches have been used to quantify pain. The first utilizes subjective reports from patients, while the second employs physiological correlates of pain, such as evoked potentials. Results from PK/PD analysis that successfully identify a relationship between drug dose, drug concentration, and effect can be used to predict the effects of drug dose on analgesic effect in individuals. The ultimate goal is to provide patients with better pain relief by understanding variables that affect the analgesic concentration/effect relationship, This review examines the available pharmacokinetic-pharmacodynamic (PK/PD) data for selected opioid and nonopioid analgesics. Even though most analgesics are used clinically in multiple doses, the majority of PK/PD studies conducted to date evaluated single dose effects. Further studies with multiple doses are required to evaluate the validity of PK/PD relationships defined from single dose studies.
引用
收藏
页码:307 / 323
页数:17
相关论文
共 50 条
  • [31] Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
    Duffull, Stephen B.
    Wright, Daniel F. B.
    Winter, Helen R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (06) : 807 - 814
  • [32] Pharmacokinetic-Pharmacodynamic Modeling of Candesartan Cilexetil in Healthy Chinese Volunteers
    Huang, Xiao-hui
    Xie, Xue-feng
    Huang, Ji-han
    Chen, Yun
    Li, Jian-chun
    Qiu, Fu-rong
    Xie, Hai-tang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (02): : 239 - 245
  • [33] Pharmacokinetic-pharmacodynamic modeling in anesthesia, intensive care and pain medicine
    Sadean, Mihai R.
    Glass, Peter S. A.
    CURRENT OPINION IN ANESTHESIOLOGY, 2009, 22 (04) : 463 - 468
  • [34] Pharmacokinetic-Pharmacodynamic Crossover Comparison of Two Levodopa Extension Strategies
    LeWitt, Peter A.
    Jennings, Danna
    Lyons, Kelly E.
    Pahwa, Rajesh
    Rabinowicz, Adrian L.
    Wang, James
    Guarnieri, Maria
    Hubble, Jean P.
    Murck, Harold
    MOVEMENT DISORDERS, 2009, 24 (09) : 1319 - 1324
  • [35] Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat
    Yin, XX
    Zhang, YD
    Luo, JP
    Huang, XP
    Shen, JP
    Ding, Y
    Huang, DK
    ACTA PHARMACOLOGICA SINICA, 1997, 18 (02): : 104 - 108
  • [36] Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach
    Shu, Cathye
    Zhou, Honghui
    Afsharvand, Mehri
    Duan, Larry
    Zhang, Hui
    Noveck, Robert
    Raible, Donald
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (04) : 472 - 481
  • [37] Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample
    Leca, FR
    Marchiset-Leca, D
    Galeani, A
    Noble, A
    Catalin, J
    ANTI-CANCER DRUGS, 1998, 9 (06) : 503 - 509
  • [38] Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development
    Dingemanse, Jasper
    Krause, Andreas
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S53 - S58
  • [39] Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty
    Standing, Joseph F.
    Hammer, Gregory B.
    Sam, Wai Johnn
    Drover, David R.
    PEDIATRIC ANESTHESIA, 2010, 20 (01) : 7 - 18
  • [40] Pharmacokinetic-Pharmacodynamic Correlation Analysis of Rhodiola crenulata in Rats with Myocardial Ischemia
    Jia, Zhixin
    Zou, Guoming
    Xie, Yongyan
    Zhang, Enning
    Yimingjiang, Mureziya
    Cheng, Xianlong
    Fang, Cong
    Wei, Feng
    PHARMACEUTICALS, 2024, 17 (05)